The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 23, 2018

Filed:

Sep. 28, 2017
Applicants:

Rutgers, the State University of New Jersey, New Brunswick, NJ (US);

The Broad Institute, Inc., Cambridge, MA (US);

Inventors:

Longqin Hu, Belle Mead, NJ (US);

Sadagopan Magesh, Highland Park, NJ (US);

Lin Chen, Piscataway, NJ (US);

Timothy Lewis, Marlborough, MA (US);

Ben Munoz, Netwonville, MA (US);

Lili Wang, Chestnut Hill, MA (US);

Assignees:

RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, New Brunswick, NJ (US);

THE BROAD INSTITUTE, INC., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/42 (2006.01); A61K 31/44 (2006.01); C07D 209/48 (2006.01); A61K 31/472 (2006.01); C07D 207/452 (2006.01); C07D 405/12 (2006.01); C07D 401/06 (2006.01); C07D 335/06 (2006.01); C07D 401/14 (2006.01); G01N 33/50 (2006.01); C07D 217/16 (2006.01); A61K 31/4725 (2006.01);
U.S. Cl.
CPC ...
C07D 209/48 (2013.01); A61K 31/472 (2013.01); A61K 31/4725 (2013.01); C07D 207/452 (2013.01); C07D 217/16 (2013.01); C07D 335/06 (2013.01); C07D 401/06 (2013.01); C07D 401/14 (2013.01); C07D 405/12 (2013.01); G01N 33/5023 (2013.01);
Abstract

A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.


Find Patent Forward Citations

Loading…